Rodgers, T., Zinzani, P. L., Marino, D., Frezzato, M., Barbui, A. M., Castellino, C., … Nowakowski, G. (2020). RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 20, pp. S265–S266).

Rodgers, Thomas, Pier Luigi Zinzani, Dario Marino, Maurizio Frezzato, Anna Maria Barbui, Claudia Castellino, Erika Meli, et al. “RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 20:S265–66, 2020.

Rodgers T, Zinzani PL, Marino D, Frezzato M, Barbui AM, Castellino C, et al. RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020. p. S265–6.

Rodgers, Thomas, et al. “RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 20, 2020, pp. S265–66.

Rodgers T, Zinzani PL, Marino D, Frezzato M, Barbui AM, Castellino C, Meli E, Conconi A, Cascavilla N, Cavallo F, Fowler NH, Feinberg B, Tillmanns S, Parche S, Fingerle-Rowson G, Winderlich M, Ambarkhane S, Salles G, Nowakowski G. RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020. p. S265–S266.